GGrantIndex
Sort

82,697 grants matching vaccine development

Community-Centered Interventions for Improved Vaccine Uptake for COVID (CIVIC)

$697,711
Erica E Marsh · University Of Michigan At Ann Arbor · R01 · FY2023 · MD

Accelerating Malaria Vaccines with a Custom Preclinical Humanized Mouse Model Platform

$697,695
Facundo Damian Batista · Massachusetts General Hospital · R01 · FY2024 · AI

Accelerating Malaria Vaccines with a Custom Preclinical Humanized Mouse Model Platform

$697,695
Facundo Damian Batista · Massachusetts General Hospital · R01 · FY2025 · AI

Risk Factors for AIDS among Drug Users: Getting Close to Zero

$697,615
Don C Des Jarlais · Icahn School Of Medicine At Mount Sinai · R01 · FY2017 · DA

Discovering the essential genome of Plasmodium falciparum

$697,594
John Adams · University Of South Florida · R01 · FY2018 · AI

NRSA Institutional Training Program in Oral Biology

$697,564
William P McArthur · University Of Florida · T32 · FY2007 · DE

Clinical analysis and therapeutic development of exosomal ACE2

$697,517
Huiping Liu · Northwestern University At Chicago · R01 · FY2025 · AI

Clinical analysis and therapeutic development of exosomal ACE2

$697,517
Huiping Liu · Northwestern University At Chicago · R01 · FY2024 · AI

Determinants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with Asthma

$697,498
William Gerald Teague · University Of Virginia · R01 · FY2024 · AI

Improving Influenza Vaccination Delivery Across a Health System by the Electronic Health Records Patient Portal

$697,497
Peter G Szilagyi · University Of California Los Angeles · R01 · FY2018 · AI

A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes

$697,459
Lbachir Benmohamed · University Of California-Irvine · R01 · FY2020 · AI

Adolescent health behaviors in the time of COVID-19

$697,455
Michele Ybarra · Center For Innovative Public Health Research · R01 · FY2023 · HD

Optimizing IMPDH inhibitors for the treatment of cryptosporidiosis

$697,416
Gregory D Cuny · University Of Houston · R56 · FY2014 · AI

Chicago Clinical Trials Unit

$697,341
Babafemi O Taiwo · Northwestern University At Chicago · UM1 · FY2023 · AI

Pathogenesis of Burkholderia mallei and pseudomallei

$697,335
Frank Gherardini · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI

The Protective and Pathologic Features of the EVD Survivor Immune System

$697,315
William Fischer · Univ Of North Carolina Chapel Hill · R01 · FY2025 · AI

Bi-functional Polymer-Attached Inhibitors of Influenza Viruses

$697,295
Jianzhu Chen · Massachusetts Institute Of Technology · U01 · FY2007 · AI

24/7 Training: Improving HIV Prevention for African American Youth

$697,175
Regina Firpo-Triplett · Monarch Media, Inc. · R44 · FY2011 · MH

Non-canonical epitope presentation and antigen processing by MHC-E

$697,170
Klaus J Frueh · Oregon Health & Science University · R01 · FY2025 · AI

Molecular Pharmacology of NKT Cell Agonists

$697,142
Luc Teyton · Scripps Research Institute, The · R01 · FY2013 · AI

Conformational Landscape of the HIV-1 Envelope Glycoproteins

$697,140
Joseph G Sodroski · Dana-Farber Cancer Inst · R01 · FY2017 · AI

Developing a multi-component vaccine harnessing potent antibody and cellular responses against the blood-stage of Plasmodium falciparum

$697,101
Prakash Srinivasan · Johns Hopkins University · R01 · FY2025 · AI

Defining targets of protective immunity to vivax malaria using human monoclonal antibodies

$697,088
Christopher L King · Case Western Reserve University · R01 · FY2024 · AI

HIV neutralization and mechanisms of cellular entry

$697,073
Sriram Subramaniam · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Quantifying Immune VS. Viral Killing of SIV Infected and Latently Infected Cells

$697,062
Ruy M Ribeiro · Los Alamos Nat Secty-Los Alamos Nat Lab · R01 · FY2016 · AI